Lilly drug beats Roche’s Avastin in advanced colon cancer
Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.
Cancer drug Erbitux extended the lives of patients with a form of advanced colon cancer more than seven months longer than those taking Roche Holding AG’s Avastin.
Elona went into receivership in June after Greenwood officials filed a foreclosure lawsuit against the firm. The company failed after receiving more than $8 million in economic development incentives from the city over the past three years.
Eli Lilly said a potential breast cancer treatment missed its main goal in a late-stage study. However, the drugmaker will seek approval to use the treatment in stomach cancer patients after ramucirumab performed better in a separate study.
The YMCA of Greater Indianapolis wants to build an 87,000-square-foot mixed-use development on a parking lot owned by Eli Lilly and Co. at the southwest corner of Alabama and South streets.
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
City officials are quietly trying to orchestrate what would be a major coup: Landing Cummins as an office anchor for a second phase of redevelopment on the former home of Market Square Arena.
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer’s.
The group that oversees Indiana’s economic development initiatives for life sciences, information technology, transportation and clean technology is moving toward a fifth thrust focused on nutrition.
By year end, the St. Vincent Health hospital system will spin off its New Hope organization for Hoosiers with development disabilities. St. Vincent New Hope will become a stand-alone organization that will continue to run group homes for its patients. New Hope started offering counseling, day programs and residential housing in 1978. About a decade later, St. Vincent joined forces with New Hope. St. Vincent Health will make a cash infusion to New Hope and also donate to New Hope more than 38 central Indiana group home properties. Jim Van Dyke, executive director of St.Vincent New Hope, said in a prepared statement, “This new phase in our history will allow us to implement even stronger programs that will enable New Hope to continue serving our clients well into the future.”
Major health insurers, including WellPoint Inc., are in line for another year of growth, thanks to Obamacare, according to Bloomberg News. Bloomberg cited Barclays Capital analyst Joshua Raskin, who in a research note late last week said the Medicaid expansion funded by Obamacare should help drive enrollment growth next year, and the health insurance exchanges in each state will wind up being a "very small" influence. WellPoint shares rose 57 cents Monday morning to $89.66 each.
Admissions at Indiana University Health hospitals in the first half of the year dipped 4.3 percent, prompting IU Health executives to give pink slips to about 800 employees, according to an announcement Thursday morning. Meanwhile, however, IU Health's business is stronger than ever, with income from operations shooting up nearly 20 percent in the first half of the year.IU Health currently has 36,000 employees, although many of them work part time. Its full-time-equivalent work force totals 27,000. For all of 2012, IU Health had revenue of $5.6 billion. IU Health’s decision comes less than three months after Indianapolis-based St. Vincent Health laid off 865 workers in late June, which was part of a 5,000-worker layoff by its parent organization, St. Louis-based Ascension Health Alliance. IU Health CEO Dan Evans said in an April interview that the hospital system is trying to cut $1 billion in expenses by 2017. So far, IU Health has been able to offset its decline in hospital admissions with an 8-percent price increase and by receiving more patient visits to its outpatient facilities. Excluding one-time items, IU Health income from operations rose 19 percent in the first half of 2013 compared to the same period in 2012. IU Health pulled in $186.3 million during those six months, compared with $156.6 million the year before. Inpatient admissions—those involving an overnight stay—had been climbing consistently throughout 2012. But then, in January, they started to fall.
Indiana University is cutting about 50 hourly workers at its Bloomington campus and shifting that work to a temporary staffing agency. Spokesman Mark Land said the move was in the works, but was accelerated so IU could avoid having to add those workers to the IU health insurance plan as required by the federal health care overhaul if they average more than 30 hours a week. Land told The Herald-Times that shifting 50 of the physical plant department's 650 jobs will also relieve the administrative task of managing the hours of seasonal workers. IU will have the Manpower agency hire the maintenance and custodial personnel after Sept. 28. The university will pay the agency an administrative fee to manage the workers.
Indianapolis-based Eli Lilly and Co. sued Canada last week, seeking $500 million in damages because the drugmaker thinks Canada’s courts violated the North American Free Trade Agreement by invalidating patents on two Lilly drugs. According to CBC News, Lilly had sought relief from Canada through arbitration, but will now take its complaint before a three-member tribunal. Lilly is suing because Canadian courts struck down some of its patents on its former bestseller Zyprexa, an antipsychotic medication, and on Strattera, a medicine to treat attention-deficit hyperactivity disorder. Lilly says the court rulings, issues from 2009 to 2011, cost Lilly hundreds of millions in sales because they allowed cheaper generic versions of the drugs to undercut Lilly’s brand-name products sooner than would have otherwise occurred. "Patent decisions in Canada over the last decade not only fly in the face of long-established international standards, but they're subjective and completely unpredictable," Doug Norman, general patent counsel for Eli Lilly, said in a prepared statement.
The nonstop connection to Silicon Valley that Indianapolis’ tech community has been clamoring for is here, but a leading advocate for the service said it doesn’t meet his industry’s needs.
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
A Miami man who helped carry out the theft of about $90 million in prescription drugs from a Eli Lilly warehouse in Connecticut pleaded guilty Monday to similar thefts in Florida, Kentucky and Virginia.
Indianapolis-based Harlan Laboratories may violate loan covenants in the next three to six months, and its ability to refinance a $280 million loan that matures in July 2014 is “highly questionable,” according to a report by Moody’s Investors Service. It’s unclear if the privately held company has an escape plan brewing. Harlan Laboratories employs about 330 people in the area and has annual sales of $326 million. The company appeared on the verge of pulling off a $305 million refinancing in February, but the deal fell apart and was shelved in April, according to Standard & Poor’s Ratings Corp. The ratings agencies say the company is not performing well enough to attract lenders. And even if it could engineer a refinancing, it likely would struggle to make the required payments. By Moody’s tally, Harlan’s “adjusted debt” is a whopping 7-1/2 times its so-called EBITDA (earnings before interest, taxes, depreciation and amortization).
Indianapolis-area hospitals are billing patients insured by their employers 264 percent more for outpatient services than what the federal Medicare program would pay for the same services for the same patients in the same facilities. That’s what researchers at the Washington, D.C.-based Center for Studying Health System Change found when they analyzed claims data for 590,000 patients, all below the age of 65, who were covered in 2011 by the union-negotiated health plans at automakers General Motors, Ford and Chrysler. The study was paid for by an organization that is funded by the automakers, the UAW and the International Union. The study compared the claims from 13 metro areas against one anther, all of them in the Midwest. Indianapolis had the highest hospital outpatient prices among all cities and the second-highest inpatient prices, behind only Kansas City. Interestingly, Kokomo had the third-highest inpatient prices and the second-highest outpatient prices. Physician prices in Indianapolis were in the middle of the pack, about 10 percent to 20 percent higher than Medicare prices. The authors of the study say hospitals’ market power, which has increased in recent years due to consolidation among hospitals and doctors, is the most likely explanation for the higher prices.
New Jersey-based Covance Inc. has formed a collaboration with the Indiana Clinical and Translational Sciences Institute to conduct early-stage clinical trials for biotechnology and pharmaceutical companies. The Indiana CTSI, which was formed by partnership of Indiana, Purdue and Notre Dame universities, will provide access to a 13,606-square-foot, 24-patient facility at IU Health University Hospital in Indianapolis. The institute also could, if needed, expand operations into a recently renovated 33,078-square-foot, 50-patient facility in the same building. This space reopens to clinical research for the first time in six years due to the efforts of the Indiana CTSI. The alliance between Covance and the Indiana CTSI was facilitated by BioCrossroads, an Indianapolis-based life sciences business development group. Covance already conducts Phase 1 clinical trials at an 80-bed facility in Evansville. But there has been a paucity of Phase 1 clinical trial work in Indianapolis since locally based drugmaker Eli Lilly and Co. shut down its clinic at the IU School of Medicine in 2007.
Residents in Princeton, N.J., have sued the municipality and Princeton University, saying the school should lose its tax-exempt status because it shares drug royalties with faculty. The case could have major repercussions for research universities.
The assets of Greenwood former drugmaker Elona Biotechnologies Inc. will be liquidated at an auction Sept. 27. Elona, which was trying to make a generic version of insulin known as a biosimilar, was put into receivership in June after the city of Greenwood filed a foreclosure action to recover more than $9.5 million in loans and incentives. Bernadette Barron, the Chicago-based receiver for Elona, hired Indianapolis-based Key Auctioneers Inc. to liquidate Elona’s assets. Those assets include an unfinished, $28 million headquarters and manufacturing facility, as well as patents and other intellectual property. Elona was founded in 1997 by two former Eli Lilly and Co. scientists. If launched, Elona’s insulin would have been a cheaper competitor to brand-name insulins made by Indianapolis-based Lilly and other companies. There are no generic versions of insulin sold around the world. Elona was seen as a rising star, and Gov. Mike Pence even visited the company in March 2012 as part of his “jobs tour,” which was a key element of his gubernatorial campaign.
On Thursday, Greenfield Mayor Richard Pasco and officials from Hancock Regional Hospital will break ground on the O3 PureMed medical waste facility. O3 PureMed is the first commercial facility in the region to dispose of medical waste using an ozone-based green technology. The facility is a partnership of Hancock Regional and Greenfield-based waste management firm Fisk Services.
Indianapolis-based Eli Lilly and Co. looked south for its latest partnership, a deal with Louisville-based health insurer Humana Inc. to conduct research to improve the health care of their members and patients. The companies will work together to identify and analyze data to improve health care quality and outcomes. The initial project will investigate the characteristics of Type 2 diabetes patients associated with increased health care costs. The companies might then study treatments that could change some of those characteristics. "We are pleased to partner with Humana on research that will help benefit patients facing a variety of diseases, including diabetes," said Dr. Dara Schuster, a medical fellow at Lilly. "Working together, we hope to provide patients with insights and guidance that will help them tailor their care to best match their individual needs."
The remnants of ill-fated Elona Biotechnologies Inc. will be auctioned on Sept. 27, presenting a rare turnkey opportunity for entrepreneurs interested in jumping into the life sciences industry.
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
The facility will include a 16-foot cyclorama—a curved wall that presents the illusion of an endless landscape.
Fellow right-wingers, our chance to stick it to the gays may not come again.
Thirty-nine protectors of pronghorn antelope, sea turtles, jaguars, ibis, puffin and other endangered species have been named as nominees for the Indianapolis Prize.